钠-葡萄糖协同转运蛋白2抑制剂导致非高血糖性糖尿病酮症酸中毒研究进展  

Research progress on sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis

作　　者：于晓濛 王宁[2] YU Xiaomeng;WANG Ning(Department of Endocrinology and Metabolism,Mudan People′s Hospital of Heze City,Heze,Shandong 274000,China;Second Department of Comprehensive Internal Medicine,the First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830000,China)

机构地区：[1]菏泽市牡丹人民医院内分泌代谢科,山东菏泽274000 [2]新疆医科大学第一附属医院综合内二科,新疆乌鲁木齐830000

出　　处：《现代医药卫生》2025年第1期196-199,204,共5页Journal of Modern Medicine & Health

基　　金：省部共建国家重点实验室(SKL-HIDCA-2020-19)。

摘　　要：钠-葡萄糖协同转运蛋白2(SGLT-2)负责肾小管中90%葡萄糖的重吸收,SGLT-2抑制剂通过抑制SGLT-2增加尿糖排泄,发挥降糖作用。SGLT-2抑制剂在降低血糖的同时,还具有心血管、肾脏保护作用,目前已在临床中广泛应用。近年来有多项研究表明,SGLT-2抑制剂可引起非高血糖性糖尿病酮症酸中毒(euDKA),因该类型患者血糖水平正常或轻度升高,易被误诊和漏诊。该文将SGLT-2抑制剂导致euDKA的可能发生机制、高危因素、临床表现进行综述,以期加强对该类药物不良反应的认识。Sodium-glucose cotransporter 2(SGLT-2)is responsible for 90%glucose reabsorption in renal tubules,and SGLT-2 inhibitors increase urinary glucose excretion by inhibiting SGLT-2,which plays a hypoglycemic role.SGLT-2 inhibitors not only reduce blood sugar,but also have cardiovascular and renal protective effects,and have been widely used in clinical practice.In recent years,a number of studies have shown that SGLT-2 inhibitors can cause euglycemic diabetic ketoacidosis(euDKA),which is easily misdiagnosed and missed due to normal or mildly elevated blood glucose levels in this type of patients.This article reviewed the possible mechanism,risk factors and clinical manifestations of euDKA caused by SGLT-2 inhibitors to enhance the understanding of the adverse effects of these drugs.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 非高血糖性糖尿病酮症酸中毒 糖尿病 综述 

分 类 号：R587.2[医药卫生—内分泌]